Picture the scene: an operating room mid-procedure, a patient’s blood pressure dropping, a clinician reaching for a vasoactive medication. In that moment of urgency, a small plastic connector at the end of an intravenous line is accessed quickly, because it has to be. That moment, repeated thousands of times a day across the country’s hospitals and surgical suites, is where a largely invisible patient safety crisis quietly unfolds.
Needleless connectors, the small caps that allow clinicians to administer IV medications without a needle, are a routine part of modern IV care. But they’re also a persistent source of contamination risk. And despite decades of education around “scrub the hub” protocols, the problem hasn’t gone away. Now, a newly FDA-authorized technology is challenging the assumption that better training alone is the answer.
When protocol meets reality
The standard protocol for disinfecting a needleless connector is well established: scrub the hub vigorously with a chlorhexidine or alcohol wipe for five to 15 seconds, let it dry, then access the line. In theory, it’s simple. In practice, in a busy operating room, ICU, or emergency department, it’s where human factors collide with clinical urgency.
Catheter-associated bloodstream infections remain one of the most preventable yet stubbornly persistent sources of harm in perioperative and critical care settings. The culprit isn’t ignorance. It’s variability in scrubbing pressure, coverage, dry time and the sheer cognitive load that clinicians carry when managing a patient in crisis. A 2024 study in Infection Control and Hospital Epidemiology specifically identified human factors, not knowledge gaps, as a primary driver of connector disinfection failures.
“You have a syringe, and you put that syringe into that IV connector and then administer your medication,” said Nick Perrenoud, MSN, RN, CEO and co-founder of HAI Solutions. “That connection moment, you actually have a high potential of transmitting bacteria or other microbes into the patient if you don’t disinfect between those connection points.” Mr. Perrenoud, himself a nurse anesthetist, has spent nearly a decade building technology designed to address exactly this problem.
Engineering out the variability
The question HAI Solutions set out to answer wasn’t how to better train clinicians; it was how to build a system that doesn’t depend on perfect human performance every single time. That shift in thinking is at the heart of what infection prevention experts call a “layered defense” approach. We already rely on it everywhere else in medicine: pulse oximetry, ventilator alarms, barcode medication scanning. Why not at the IV connector?
The Carlsbad, Calif.-based company’s answer is the QIKCAP system, a combination of a reusable handheld ultraviolet-C emitter and a single-use cap embedded with a chromatic dosimeter. When the UVC light is applied to the connector, the cap’s dosimeter changes from yellow to magenta, providing the clinician with immediate, visible confirmation that a sufficient dose of germicidal energy has been delivered. The entire process takes 10 seconds and can be viewed here.
FDA authorization and what it actually means
In December 2025, the FDA granted de novo classification to the QIKCAP system, establishing a brand-new Class II medical device category, “Ultraviolet light-based microbial reduction device for luer-activated valves.” This wasn’t a rubber stamp. Creating a new device category means the FDA found the science compelling enough to write the regulatory rulebook from scratch. Under testing conditions, the combination of a 3.15% CHG/70% IPA wipe and the QIKCAP system achieved a 4-log reduction in key bloodstream infection pathogens: Staphylococcus aureus, Klebsiella pneumoniae, Staphylococcus epidermidis and Enterobacter cloacae.
Independent bench-top testing at Montana State University’s Center for Biofilm Engineering in Bozeman pushed the conditions even further by introducing blood contamination and worst-case soiling to simulate what actually happens in a clinical environment. Under those conditions, the combined CHG/IPA-plus-UVC approach achieved approximately a 5-log reduction in microbial load, substantially outperforming either method alone.
The FDA was clear, and it’s worth being clear here too: the QIKCAP system is designed to supplement, not replace, manual disinfection. And while the lab evidence is compelling, a direct correlation to clinical CABSI reduction in real-world settings hasn’t yet been established. That work, the prospective clinical trials and implementation studies, still lies ahead.
“This de novo grant is a huge accomplishment for the HAI Solutions team,” Perrenoud said following the December 2025 announcement. “We are proud to bring this innovative technology to market, addressing a critical need in IV connector maintenance and protection.”
The bigger picture: A systems problem, not a people problem
One of the most important reframes in this conversation is this: needleless connector contamination is not primarily an education problem. Clinicians know how to scrub the hub. The challenge is that healthcare systems have, for decades, relied on near-perfect human performance under conditions specifically designed to undermine it: high cognitive load, frequent interruptions, time pressure, and physiologic urgency.
A frequently cited 2016 study published in Anesthesiology found that microorganisms capable of causing infection were detected in roughly 6.3% of inline filters downstream of routine anesthetic drug administration. Furthermore, the organisms identified (S. aureus, S. epidermidis and K. pneumoniae) were strikingly similar to those in the UVC connector research. The contamination isn’t coming from isolated catastrophic failures. It’s cumulative, arising from repeated small lapses across countless access events.
This is where engineering controls, the same philosophy that gave us needle safety systems and infusion pump guardrails, become essential. Not because clinicians are careless, but because no system that depends entirely on flawless human execution under stressful conditions will ever be truly safe.
Making the business case: The QIKulator
For any new technology to take hold in a hospital, it must survive value analysis committee scrutiny, and that means translating clinical promise into financial reality. HAI Solutions has built a tool specifically for that conversation: the QIKulator, a publicly available financial impact calculator available here.
The numbers behind the tool are sobering. According to the Agency for Healthcare Research and Quality, each CABSI incurs an attributable cost of $48,108, which includes direct treatment costs, extended length of stay, and downstream complications. With an average of 13.4 excess hospital days per infection, a single preventable CABSI represents a significant financial and human toll.
The QIKulator lets infection prevention teams and hospital administrators model their own facility’s risk profile. Users enter the number of enrolled beds and their baseline CABSI rate, then adjust two attribution sliders: the share of CABSIs attributable to connectors (supported at 30% to 50% in the literature) and the expected reduction from QIKCAP deployment (supported at 50% to 70% in peer-reviewed research on connector disinfection). The tool then calculates the estimated CABSIs prevented, the direct costs avoided, and the return on investment at the standard subscription price of $89 per bed per month with unlimited cap usage.
HAI Solutions has also built in an optional Premium Cap Recycle Service, which reduces medical waste and hospital carbon footprint. The QIKulator calculates environmental impact in parallel: CO2 emissions avoided, plastic diverted from landfills, and carbon cost savings — a nod to the growing sustainability mandates many hospital systems now face. Importantly, the tool is deliberately conservative in its attribution, crediting QIKCAP only for connector-related CABSIs rather than the full bundle effect. That defensibility is by design and built to hold up in a VAC meeting.
What comes next
HAI Solutions is targeting the commercial launch of the QIKCAP system beginning in October 2026, with initial rollout in the United States, New Zealand, China, Hong Kong and Macau. Early deployment is expected to focus on high-acuity environments (e.g., operating rooms, ICUs, emergency departments) where the combination of frequent needleless access and intense workflow demands makes it most difficult to consistently guarantee manual disinfection.
But technology is only part of the answer. Successful implementation will require hospitals, infection prevention teams, and perioperative leadership to think seriously about workflow integration, usability, and outcome measurement. If the QIKCAP system or technologies like it are going to earn a place in the standard of care, the clinical data needs to follow the lab data. That means structured pilot programs, prospective CABSI surveillance, and honest evaluation.
For anesthesia professionals, this is an opportunity worth taking seriously. They sit at the exact intersection of infection prevention, workflow design and patient safety science. They’re among the clinicians most likely to be accessing IV connectors in the highest-stakes moments of a patient’s care. The question isn’t whether needleless connector contamination is a problem worth solving. It is. The question is whether the field is ready to embrace the engineering-based solutions that give the next generation of patients a better chance.
Mark Gabot, DNP, CRNA, FAANA, FASE, is academic and clinical faculty at the Kaiser Permanente School of Anesthesia. He serves as a consultant for HAI Solutions.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.